Search the Site
Follow TheCancerLetter on Twitter
join our mailing list

Enter your name and email address to receive an update when we post new content.

IP Login

 

The Cancer Letter Inc.
PO Box 9905
Washington
DC 20016
Tel: 202-362-1809
Fax: 202-379-1787
publication date: Mar 31, 2016
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Ovarian Cancer

Study: Reolysin-Paclitaxel Combination Demonstrates Higher Response than Paclitaxel Therapy Alone

 

Updated results from a phase II trial of Reolysin and paclitaxel in ovarian cancer patients showed that an intent-to-treat analysis of tumor response, as assessed by CA-125 antigen levels, demonstrated statistically significantly higher full response rates and stable disease or better rates in the test arm compared to paclitaxel alone.

The rate of full responses in the combination arm was 9.26 percent, compared to 1.85 percent in the control arm (p = 0.0196). The rate of stable disease or better in the test arm was 44.44 percent, compared with 24.08 percent in the control arm (p = 0.0096).



To access this members-only content, please log in.

If you're not a subscriber why not join today?

If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Letter